Subscribe
shutterstock_1661365084_sundry_photography
Sundry Photography / Shutterstock.com
8 January 2021AmericasRory O'Neill

Roche urges SCOTUS to cancel Illumina patent win

Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit won’t revisit revived Illumina DNA test patents
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
Americas
Fed Circuit restores two Illumina DNA patents in blow to Roche
19 March 2020   The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Federal Circuit won’t revisit revived Illumina DNA test patents
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
Americas
Fed Circuit restores two Illumina DNA patents in blow to Roche
19 March 2020   The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.

More on this story

Americas
Federal Circuit won’t revisit revived Illumina DNA test patents
6 August 2020   The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
Americas
Fed Circuit restores two Illumina DNA patents in blow to Roche
19 March 2020   The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
Americas
SCOTUS weighs future of assignor estoppel
11 January 2021   The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.

More features

Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court